Growth hormone treatment of adolescents with growth hormone deficiency (GHD) during the transition period: Results of a survey among adult and paediatric endocrinologists from Italy. Endorsed by SIEDP/ISPED, AME, SIE, SIMA

G. Aimaretti, R. Attanasio, S. Cannavò, M. C. Nicoletti, R. Castello, C. Di Somma, P. Garofalo, L. Iughetti, S. Loche, M. Maghnie, L. Mazzanti, G. Saggese, M. Salerno, G. Tonini, V. Toscano, S. Zucchini, M. Cappa

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Treatment of adolescents with growth hormone deficiency (GHD) during the transition period is a controversial issue. This paper is a contribution from the Italian community of paediatric and adult endocrinologists surveyed in a Delphi panel. The Delphi method is a structured communication technique, originally developed as a systematic, interactive forecasting method that relies on a panel of experts. The experts answer questionnaires in two or more rounds. There was substantial agreement on the definition of the problems associated with the diagnosis and treatment of adolescents with GHD in the transition period, as well as on the identification of the controversial issues which need further studies. There is general consensus on the need of re-testing all isolated idiopathic GHD after at least 30-day withdrawn from treatment, while in patients with multiple pituitary deficiency and low IGF-I levels there is generally no need to re-test. In patients with permanent or confirmed GHD, a starting low rhGH dose (0.01-0.03 mg per day) to be adjusted according to IGF-I concentrations is also widely accepted. For those continuing treatment, the optimal therapeutic schedule to obtain full somatic maturation, normalization of body composition and bone density, cardiovascular function and Quality of Life, need to be evaluated.

Original languageEnglish
Pages (from-to)377-382
Number of pages6
JournalJournal of Endocrinological Investigation
Volume38
Issue number3
DOIs
Publication statusPublished - Mar 5 2015

Fingerprint

Italy
Growth Hormone
Pediatrics
Insulin-Like Growth Factor I
Pituitary Dwarfism
Therapeutics
Body Composition
Bone Density
Consensus
Appointments and Schedules
Communication
Quality of Life
Endocrinologists
methylamphotericin B
Surveys and Questionnaires

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Growth hormone treatment of adolescents with growth hormone deficiency (GHD) during the transition period : Results of a survey among adult and paediatric endocrinologists from Italy. Endorsed by SIEDP/ISPED, AME, SIE, SIMA. / Aimaretti, G.; Attanasio, R.; Cannavò, S.; Nicoletti, M. C.; Castello, R.; Di Somma, C.; Garofalo, P.; Iughetti, L.; Loche, S.; Maghnie, M.; Mazzanti, L.; Saggese, G.; Salerno, M.; Tonini, G.; Toscano, V.; Zucchini, S.; Cappa, M.

In: Journal of Endocrinological Investigation, Vol. 38, No. 3, 05.03.2015, p. 377-382.

Research output: Contribution to journalArticle

Aimaretti, G. ; Attanasio, R. ; Cannavò, S. ; Nicoletti, M. C. ; Castello, R. ; Di Somma, C. ; Garofalo, P. ; Iughetti, L. ; Loche, S. ; Maghnie, M. ; Mazzanti, L. ; Saggese, G. ; Salerno, M. ; Tonini, G. ; Toscano, V. ; Zucchini, S. ; Cappa, M. / Growth hormone treatment of adolescents with growth hormone deficiency (GHD) during the transition period : Results of a survey among adult and paediatric endocrinologists from Italy. Endorsed by SIEDP/ISPED, AME, SIE, SIMA. In: Journal of Endocrinological Investigation. 2015 ; Vol. 38, No. 3. pp. 377-382.
@article{0fd0b83af57247039ae7e1ef63ad707b,
title = "Growth hormone treatment of adolescents with growth hormone deficiency (GHD) during the transition period: Results of a survey among adult and paediatric endocrinologists from Italy. Endorsed by SIEDP/ISPED, AME, SIE, SIMA",
abstract = "Treatment of adolescents with growth hormone deficiency (GHD) during the transition period is a controversial issue. This paper is a contribution from the Italian community of paediatric and adult endocrinologists surveyed in a Delphi panel. The Delphi method is a structured communication technique, originally developed as a systematic, interactive forecasting method that relies on a panel of experts. The experts answer questionnaires in two or more rounds. There was substantial agreement on the definition of the problems associated with the diagnosis and treatment of adolescents with GHD in the transition period, as well as on the identification of the controversial issues which need further studies. There is general consensus on the need of re-testing all isolated idiopathic GHD after at least 30-day withdrawn from treatment, while in patients with multiple pituitary deficiency and low IGF-I levels there is generally no need to re-test. In patients with permanent or confirmed GHD, a starting low rhGH dose (0.01-0.03 mg per day) to be adjusted according to IGF-I concentrations is also widely accepted. For those continuing treatment, the optimal therapeutic schedule to obtain full somatic maturation, normalization of body composition and bone density, cardiovascular function and Quality of Life, need to be evaluated.",
author = "G. Aimaretti and R. Attanasio and S. Cannav{\`o} and Nicoletti, {M. C.} and R. Castello and {Di Somma}, C. and P. Garofalo and L. Iughetti and S. Loche and M. Maghnie and L. Mazzanti and G. Saggese and M. Salerno and G. Tonini and V. Toscano and S. Zucchini and M. Cappa",
year = "2015",
month = "3",
day = "5",
doi = "10.1007/s40618-014-0201-7",
language = "English",
volume = "38",
pages = "377--382",
journal = "Journal of Endocrinological Investigation",
issn = "0391-4097",
publisher = "Springer International Publishing",
number = "3",

}

TY - JOUR

T1 - Growth hormone treatment of adolescents with growth hormone deficiency (GHD) during the transition period

T2 - Results of a survey among adult and paediatric endocrinologists from Italy. Endorsed by SIEDP/ISPED, AME, SIE, SIMA

AU - Aimaretti, G.

AU - Attanasio, R.

AU - Cannavò, S.

AU - Nicoletti, M. C.

AU - Castello, R.

AU - Di Somma, C.

AU - Garofalo, P.

AU - Iughetti, L.

AU - Loche, S.

AU - Maghnie, M.

AU - Mazzanti, L.

AU - Saggese, G.

AU - Salerno, M.

AU - Tonini, G.

AU - Toscano, V.

AU - Zucchini, S.

AU - Cappa, M.

PY - 2015/3/5

Y1 - 2015/3/5

N2 - Treatment of adolescents with growth hormone deficiency (GHD) during the transition period is a controversial issue. This paper is a contribution from the Italian community of paediatric and adult endocrinologists surveyed in a Delphi panel. The Delphi method is a structured communication technique, originally developed as a systematic, interactive forecasting method that relies on a panel of experts. The experts answer questionnaires in two or more rounds. There was substantial agreement on the definition of the problems associated with the diagnosis and treatment of adolescents with GHD in the transition period, as well as on the identification of the controversial issues which need further studies. There is general consensus on the need of re-testing all isolated idiopathic GHD after at least 30-day withdrawn from treatment, while in patients with multiple pituitary deficiency and low IGF-I levels there is generally no need to re-test. In patients with permanent or confirmed GHD, a starting low rhGH dose (0.01-0.03 mg per day) to be adjusted according to IGF-I concentrations is also widely accepted. For those continuing treatment, the optimal therapeutic schedule to obtain full somatic maturation, normalization of body composition and bone density, cardiovascular function and Quality of Life, need to be evaluated.

AB - Treatment of adolescents with growth hormone deficiency (GHD) during the transition period is a controversial issue. This paper is a contribution from the Italian community of paediatric and adult endocrinologists surveyed in a Delphi panel. The Delphi method is a structured communication technique, originally developed as a systematic, interactive forecasting method that relies on a panel of experts. The experts answer questionnaires in two or more rounds. There was substantial agreement on the definition of the problems associated with the diagnosis and treatment of adolescents with GHD in the transition period, as well as on the identification of the controversial issues which need further studies. There is general consensus on the need of re-testing all isolated idiopathic GHD after at least 30-day withdrawn from treatment, while in patients with multiple pituitary deficiency and low IGF-I levels there is generally no need to re-test. In patients with permanent or confirmed GHD, a starting low rhGH dose (0.01-0.03 mg per day) to be adjusted according to IGF-I concentrations is also widely accepted. For those continuing treatment, the optimal therapeutic schedule to obtain full somatic maturation, normalization of body composition and bone density, cardiovascular function and Quality of Life, need to be evaluated.

UR - http://www.scopus.com/inward/record.url?scp=84924417653&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924417653&partnerID=8YFLogxK

U2 - 10.1007/s40618-014-0201-7

DO - 10.1007/s40618-014-0201-7

M3 - Article

C2 - 25362629

AN - SCOPUS:84924417653

VL - 38

SP - 377

EP - 382

JO - Journal of Endocrinological Investigation

JF - Journal of Endocrinological Investigation

SN - 0391-4097

IS - 3

ER -